Works matching IS 21534888 AND DT 2019 AND VI 10 AND IP 1

Results: 31

Trump Administration Moves to Curb Drug Rebates in Medicare, Medicaid: Proposal, likely to draw industry resistance, would limit rebates drugmakers give to third parties.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 42

By:

Armour, Stephanie;
Walker, Joseph

Publication type:

Article

Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 41
Publication type:: Article

Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 41

By:

Doyle, Chase

Publication type:

Article

Economic Implications of Inpatient versus Outpatient Autologous Transplant for Patients with Multiple Myeloma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 40

By:

Doyle, Chase

Publication type:

Article

Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 39
Publication type:: Article

Inpatient Costs for Children and Young Adults with Acute Lymphoblastic Leukemia Higher at Specialized Cancer Centers, but for a Good Reason?

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 39

By:

Doyle, Chase

Publication type:

Article

Tisagenlecleucel Leads to High Rates of Durable Response in Relapsed, Refractory DLBCL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 38
Publication type:: Article

Oral Rigosertib plus Azacitidine Combination Shows Promising Results in High-Risk Myelodysplastic Syndromes.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 31

By:

Doyle, Chase

Publication type:

Article

Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk Myelodysplastic Syndromes.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 30

By:

Kuznar, Wayne

Publication type:

Article

Elotuzumab, Lenalidomide, and Dexamethasone Combination Demonstrates High Response Rate in High-Risk Smoldering Multiple Myeloma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 29

By:

Doyle, Chase

Publication type:

Article

Daratumumab Enhances Remissions When Added to Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 28

By:

Kuznar, Wayne

Publication type:

Article

Results from the Phase 3 iLLUMINATE Study . . .

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 27
Publication type:: Article

Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 27
Publication type:: Article

Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 27
Publication type:: Article

Results from the Phase 3 iLLUMINATE Study: Ibrutinib plus Obinutuzumab as First-Line Treatment in Patients with CLL/SLL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 26
Publication type:: Article

Ibrutinib Alone or in Combination with Rituximab Produces Superior PFS Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 26
Publication type:: Article

Phase 3 MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/ Refractory CLL.

Published in:: Value-Based Cancer Care, 2019, v. 10, n. 1, p. 23
Publication type:: Article

Dual-Specific CAR T-Cell Therapy Targets CD19 and CD22 in Patients with Acute Lymphoblastic Leukemia.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 25

By:

Doyle, Chase

Publication type:

Article

Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 24

By:

Kuznar, Wayne

Publication type:

Article

AMG 420, a Novel BiTE, Shows Impressive Responses in Heavily Treated Patients with Multiple Myeloma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 24

By:

Kuznar, Wayne

Publication type:

Article

First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 23

By:

Kuznar, Wayne

Publication type:

Article

First-Line Enasidenib Achieves Complete Remission in Older Patients with Acute Myeloid Leukemia and IDH2 Mutation.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 19

By:

Bankhead, Charles

Publication type:

Article

Researchers Identify First Mutation to Explain Resistance to Venetoclax.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 18

By:

Starr, Phoebe

Publication type:

Article

Next-Generation BTK Inhibitor Highly Active in Relapsed or Refractory Mantle-Cell Lymphoma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 17

By:

Kuznar, Wayne

Publication type:

Article

Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 11

By:

Starr, Phoebe

Publication type:

Article

Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 10

By:

Starr, Phoebe

Publication type:

Article

Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 9

By:

Starr, Phoebe

Publication type:

Article

High Incidence of Adverse Events Linked to Significant Economic Burden in Patients with Chronic Lymphocytic Leukemia.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1

By:

Doyle, Chase

Publication type:

Article

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1

By:

Bankhead, Charles

Publication type:

Article

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1

By:

Starr, Phoebe

Publication type:

Article

Rapid Progress in Aggressive Hematologic Malignancies Highlighted at ASH 2018.

Published in:

Value-Based Cancer Care, 2019, v. 10, n. 1, p. 1

By:

Kuznar, Wayne

Publication type:

Article